NOS2 and neoplasm: Accordingly, entinostat, a class I HDAC inhibitor, in combination with anti-PD-1 antibodies, reduces the expression of ARG1, iNOS, and COX2 in MDSCs, finally inhibiting their immunosuppressive capacity and delaying tumor growth in mice [126].